TVTX: Volume dana dhuwit perusahaan Retrophin

Logo grafis travere.com (TVTX)

Travere Therapeutics specializes in nephrology, developing Filspari to combat rare kidney pathologies under the protection of exclusive rights. This chart illustrates the cash balance presented on GURU.Markets via the 0.47 level, which captures the latest values. A strong team of scientists and close ties with patients guarantee staff loyalty, while reliable contract manufacturing capacities ensure the stable production of drugs.

Sisa dhuwit perusahaan: Travere Therapeutics Inc (TVTX) kanggo 04.07.2022 - 21.11.2026

Rincian metrik keuangan lan pasar Retrophin (TVTX)

- rega saiki lan proyeksi nilai saham:
Ringkesan analisis perusahaan:Travere Therapeutics
Sampel barang Travere Therapeutics Inc

The development of the orphan drug portfolio of Travere Therapeutics (TVTX) requires significant capital to maintain operational stability. By analyzing the company's cash position, investors assess the level of liquidity needed to cover capital expenditures and M&A to avoid business stagnation amid geopolitical risks regarding raw material supplies from Asia, thereby confirming the company's financial autonomy and long-term viability.